SOURCE: SomaLogic


December 17, 2015 03:00 ET

VU University Medical Center Amsterdam and SomaLogic Announce First Continental European Deployment of SOMAscan® Proteomics Assay

AMSTERDAM, THE NETHERLANDS, and BOULDER CO--(Marketwired - December 17, 2015) - SomaLogic, Inc., and VU University Medical Center Amsterdam (VUmc), announced today that the SOMAscan® assay, a breakthrough proteomics platform, will be deployed at VUmc for its scientists' use in multiple different biomedical research projects. The assay will be performed under the direction of Dr. Charlotte E Teunissen.

"We are delighted that VUmc will be the first institution in mainland Europe to offer its researchers access to this cutting-edge proteomics platform," said Dr. Teunissen. "I believe that many critical new insights into biology and disease will come from our deployment of the SOMAscan assay."

Compared to other current proteomic technologies, SomaLogic's platform gives researchers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,310 different SOMAmer reagents, efficiently, accurately, and rapidly measures proteins across a wide range of concentrations in small volumes of multiple biological sample types, accelerating the discovery of biomarkers across a wide range of diseases and conditions.

"We are excited to partner with VUmc to expand access to our technology in Europe," said Byron Hewett, Chief Executive Officer of SomaLogic. "Under the direction of Dr. Teunissen, we believe that the SOMAscan assay will accelerate many new discoveries and their applications in biomedical research at VUmc and beyond."

VUmc is the first major research center on the European mainland to deploy the SOMAscan platform onsite. SomaLogic is continuing to expand access to the platform through additional placements to be announced over the next several months.

For more information about VUmc, please visit For more information about SomaLogic, please visit

About VUmc

VU University Medical Center's core business consists of patient care, scientific research, and education. Its focal areas in care and research are: cancer and the immune system, the brain, movement, vital functions and extramural care. Every year, 55.000 patients are admitted (some for day therapy), over 336.000 patients visit the outpatient clinic and 34.000 visit the Emergency Department. About 2.400 medical students receive an education. The results of scientific research are presented in about 2.400 scientific publications and reports each year, including about 150 PhD theses.

VU University Medical Center is a member of the Netherlands Federation of University Medical Centers (NFU). The NFU is a collaborative venture of the eight university medical centres (UMCs) in the Netherlands.

About SomaLogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company's mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at

Contact Information